Stocks traded lower Tuesday afternoon, giving back ground a day after the S&P 500 and Dow Jones Industrial Average closed at records in a rally fueled by progress toward a COVID-19 vaccine.
Worries about the near-term economic outlook also appeared to weigh on the market as investors tracked a surge in COVID-19 infections and slowing retail sales growth.
What are major benchmarks doing?
The Dow Jones Industrial Average DJIA, -0.55% dropped 162 points, or 0.5%, to 29,787, while the S&P 500 SPX, -0.47% fell 13 points, or 0.4%, to 3,613. The tech-heavy Nasdaq Composite Index COMP, -0.20% declined 14 points, or 0.1%, at 11,909.
The Dow on Monday advanced 470.63 points, or 1.6%, to close at 29,950.44, marking its first record finish since Feb. 12 and leaving it on the doorstep of the psychologically important 30,000 milestone. The S&P 500 rose 41.76 points, or 1.2%, to close at a record 3,626.91. The Nasdaq Composite rose 94.84 points, or 0.8%, to end at 11,924.13.
What’s driving the market?
Stocks were under pressure Tuesday, with a report showing the weakest retail sales in months, driving markets down from their early records to start the week. Analysts are on the watch for signs that the U.S. consumer, resilient to the shocks from the coronavirus pandemic thus far, would start to buckle as federal unemployment benefits taper.
Data showed that October retail sales rose 0.3% in October — matching the consensus forecast produced by a MarketWatch survey of economists, but confirming the weakest rise in six months.
“Waning momentum in consumer activity highlights the lingering fragility of individuals and households as local restrictions and safety protocols continue to impact incomes, revenues and opportunities,” said Lindsey Piegza, chief economist for Stifel.
Meanwhile, the U.S. saw 166,581 new COVID-19 cases on Monday, and at least 796 people died, according to a New York Times tracker. In the past week, the U.S. has averaged 155,442 cases a day, up 82% from the average two weeks ago and cases are rising in 50 states and territories.
The market’s pause reflects investor uncertainty over the near-term outlook as they attempt to balance the promise of a vaccine with rising cases, and shrinking economic activity in some parts of the economy. A lack of progress toward additional economic aid out of Washington also was hampering a more robust move by markets, said Keith Buchanan, senior portfolio manager at Globalt, in an interview.
Stocks rose Monday after Moderna Inc. MRNA, -4.90% said its COVID-19 vaccine candidate was 94.5% effective in preventing infections during a late-stage trial. A week earlier, Pfizer Inc. PFE, +1.84% and BioNTech SE BNTX, -5.01% announced their vaccine candidate was more than 90% effective.
Prospects for a vaccine prompted a rotation away from pandemic winners, including large-cap tech and internet stocks, in favor of more economically sensitive stocks.
That said, Buchanan argued that recent outperformance by cyclical stocks versus large-cap tech and other pandemic winners was unlikely to prove to be overdone. The gap between growth and value stocks had grown even more substantially stretched over the last eight months, he said.
But analysts said uncertainty about the consumer could undercut the rally, putting the focus on retail sales data and other measures of consumer activity.
Sluggish spending in October echoes the experience of retailers earlier this year during the first COVID-19 wave, said Jim Baird, chief investment officer for Plante Moran Financial Advisors.
“Surging coronavirus cases pose a clear risk, as social distancing measures are being reimposed across much of the country. Increased restrictions are likely to hinder consumer spending in the months ahead, particularly for bricks-and-mortar stores and restaurants that rely on in-person shopping an dining, respectively,” he said.
In other economic data, industrial production rose 1.1% in October, the Federal Reserve reported, in line with expectations. Capacity utilization rose to 72.8% from 72% in September.
Ultralow interest rates, helped the National Association of Home Builders’ monthly confidence index to rise five points to a record-high reading of 90 in November, the trade group said Tuesday.
Which companies are in focus?
- Walmart Inc. WMT, -2.01% shares were down 0.5% after the retail giant and Dow component reported results that topped expectations.
- Fellow Dow component Home Depot Inc. HD, -2.54% saw shares fall more than 2%, despite the home improvement retailer reporting fiscal third-quarter profit that beat expectations and sales that rose well above forecasts.
- Shares of Tesla Inc. TSLA, +8.21% rose 9% after S&P Dow Jones Indices late Monday said it would add the electric-car maker to the S&P 500 beginning Dec. 21.
- Shares of drugstore chains tumbled after e-commerce giant Amazon.com Inc. AMZN, +0.14% said it would launch an online pharmacy. Walgreens Boots Alliance Inc. WBA, -9.62% shares were down nearly 9%, while CVS Health Corp. CVS, -8.61% shares dropped 8.6% and Rite Aid Corp. RAD, -16.29% shares were off around 16%. Amazon shares were up 0.9%.
How are other markets faring?
December gold futures GCZ20, -0.38% declined by $2.70, or 0.1%, to settle at $1,885.10 an ounce on Comex. The U.S. crude benchmark CL.1, +0.26% rose 0.3% to $41.49 a barrel on the New York Mercantile Exchange.
The ICE U.S. Dollar Index DXY, -0.22%, a measure of the currency against a basket of six major rivals, was off 0.3%.